Inventaire - your friends and communities are your best library

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists

author

Baptist Gallwitz

2000 -

published in: The review of diabetic studies : RDS

date of publication: 2009-12-30

Cites articles 128

Date

Title

Authors

2009-08-14

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
2009-06-08

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Eduard Montanya, Giorgio Sesti, Julio Rosenstock, John Buse, Edelmiro Menéndez Torre, Marcin J Zychma
2009-06-01

Unraveling the science of incretin biology
2009-06-01

Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus
2009-04-28

Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop

Christian Widmann, Evrim Jaccard
2009-04-23

Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis

Diana L Williams
2009-04-09

GLP-1: broadening the incretin concept to involve gut motility
2009-04-01

Insulin signaling in alpha cells modulates glucagon secretion in vivo
2009-03-01

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Stephen Colagiuri, Michel Marre
2009-03-16

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Bernard Zinman, John Buse, John E. Gerich
2009-03-01

GLP-1 agonist-based therapies: an emerging new class of antidiabetic drug with potential cardioprotective effects
2009-05

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Hannele Yki-Järvinen, Robert J. Heine, Marja-Riitta Taskinen, Michaela Diamant
2009-01-16

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice

Daniel J. Drucker
2009-01-09

A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules

Anthony E Dear, Lotte Bjerre Knudsen
2009-12-01

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

David Matthews
2009-02-06

GLP-1 regulates gastroduodenal motility involving cholinergic pathways
2009-02-01

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury

Gerard Pasterkamp, Paul Steendijk, Dominique de Kleijn, Imo Hoefer, Pieter A Doevendans, Hans Kemperman, Cees W J Verlaan
2009-04-01

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

David D Dore, John D Seeger
2008-12-12

The role of incretins in glucose homeostasis and diabetes treatment

Josephine M. Egan
2008-10-17

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study
2008-10-04

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

John Buse, Daniel J. Drucker
2008-09-02

New treatments in type 2 diabetes: a focus on the incretin-based therapies
2008-07-31

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes

Ivan Quesada, Eva Tudurí, Angel Nadal
2008-07-01

The effects of pharmacologic agents for type 2 diabetes mellitus on body weight
2008-02-01

GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival
2008-02-01

Pancreatic alpha-cell dysfunction in diabetes

Patrice D. Cani, Claude Knauf
2008-07-15

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

Cendrine Cabou, Corinne Leloup, Christophe Magnan, Daniel J. Drucker
2008-07-01

Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility

Jens Juul Holst
2008-05-16

Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake

Randy J. Seeley, Stephen C. Woods
2008-05-01

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors
2008-05-05

Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study

Michael J Pencina, Ramachandran S. Vasan, Caroline S Fox, Nina P Paynter
2008-04-21

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

Daniel J. Drucker

Article - wd:Q33521451

Welcome to Inventaire

the library of your friends and communities

learn more